Mstarin contains midostaurin, an oral anti-cancer medication primarily used in the treatment of specific blood cancers. It belongs to a class of drugs known as multi-targeted kinase inhibitors, designed to interfere with the abnormal growth of cancer cells. Midostaurin plays a crucial role in targeting genetic mutations that drive cancer, particularly in patients with acute myeloid leukemia and systemic mastocytosis.

This medication represents a significant advancement for patients whose cancers are driven by particular genetic mutations, such as FLT3, offering a targeted therapy option that was not available before.

Midostaurin works by inhibiting several receptor tyrosine kinases, with a primary focus on:

• FLT3 (FMS-like tyrosine kinase 3) mutations, which are present in a subset of acute myeloid leukemia cases

• KIT, PDGFR, and other kinases involved in cell growth and proliferation

By blocking these abnormal signaling pathways, midostaurin helps:

• Reduce the proliferation of malignant cells

• Induce programmed cell death or apoptosis in cancerous cells

• Slow down or stop the spread of disease

  Uses

  Mstarin (midostaurin) is used in the treatment of:

  • Acute Myeloid Leukemia (AML) that has FLT3 mutations
    It is usually given in combination with standard chemotherapy for newly diagnosed patients.

  • Aggressive Systemic Mastocytosis

  • Systemic Mastocytosis with Associated Hematological Neoplasm

  • Mast Cell Leukemia
    These are rare blood disorders characterized by the overproduction of mast cells and require targeted treatment such as midostaurin.

    Adverse Effects

    Like all anti-cancer therapies, Mstarin may cause side effects. Regular monitoring and supportive care are important during treatment.

    Common Side Effects

    • Nausea and vomiting

    • Diarrhea

    • Fatigue or weakness

    • Headache

    • Fever and infections

    • Nosebleeds or bleeding tendencies

    • Skin rash